Cytodyn Inc CYDY:OTCQB

*Data is delayed | Exchange | USD
Last | 03/27/24 EDT
0.1666UNCH (UNCH)
52 week range
0.15 - 0.42
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.1666
  • 52 Week High0.42
  • 52 Week High Date12/07/23
  • 52 Week Low0.15
  • 52 Week Low Date10/23/23

Key Stats

  • Market Cap164.277M
  • Shares Out986.06M
  • 10 Day Average Volume1.31M
  • Dividend-
  • Dividend Yield-
  • Beta0.18
  • YTD % Change-14.56

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.1666
  • 52 Week High0.42
  • 52 Week High Date12/07/23
  • 52 Week Low0.15
  • 52 Week Low Date10/23/23
  • Market Cap164.277M
  • Shares Out986.06M
  • 10 Day Average Volume1.31M
  • Dividend-
  • Dividend Yield-
  • Beta0.18
  • YTD % Change-14.56

RATIOS/PROFITABILITY

  • EPS (TTM)-0.06
  • P/E (TTM)-2.93
  • Fwd P/E (NTM)-1.39
  • EBITDA (TTM)-15.671M
  • ROE (TTM)-566.11%
  • Revenue (TTM)-
  • Gross Margin (TTM)-33,787.11%
  • Net Margin (TTM)-89,045.78%
  • Debt To Equity (MRQ)-28.78%

EVENTS

  • Earnings Date04/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cytodyn Inc

 

Profile

MORE
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical...
Tanya Urbach
Independent Chairman of the Board
Jacob Lalezari M.D.
Chief Executive Officer
Mitchell Cohen
Interim Chief Financial Officer
Tyler Blok
Executive Vice President - Legal Affairs, Joint Company Secretary
Address
1111 Main St Ste 660
Vancouver, WA
98660-2970
United States

Top Peers

SYMBOLLASTCHG%CHG
NVCT
Nuvectis Pharma Inc
8.34+0.09+1.09%
ACHV
Achieve Life Sciences Inc
4.52-0.14-3.00%
ALDX
Aldeyra Therapeutics Inc
3.08+0.16+5.48%
GALT
Galectin Therapeutics Inc
2.41+0.04+1.69%
RGLS
Regulus Therapeutics Inc
2.88+0.04+1.23%